Mergers and Acquisitions

• Future Elctronics Inc. in its $3.8 billion sale to WT Microelectronics (TAIEX: 3036)
• NET Power, LLC (NYSE: NPWR) in its $1.459 billion business combination with Rice Acquisition Corp. II
• Monterey Capital Acquisition Corporation (Nasdaq:MCAC) in its proposed $145 million business combination with ConnectM Technology Solutions, Inc.
• GRI Bio, Inc. (Nasdaq: GRI) in its reverse merger with Vallon Pharmaceuticals, Inc. 
• Biolog-id S.A. in its proposed $312 million business combination with Genesis Growth Tech Acquisition Corp. (Nasdaq: GGAA)
• Hyperfine, Inc. (Nasdaq: HYPR) and Liminal Sciences in their $580 million business combination with HealthCor Catalio Acquisition Corp.
• The Metals Company (Nasdaq: TMC), formerly DeepGreen Metals Inc., in its $2.9 billion business combination with Sustainable Opportunities Acquisition Corporation
• Quantum-Si Incorporated (Nasdaq:QSI) in its $1.46 billion business combination with HighCape Capital Acquisition Corp.
• Butterfly Network, Inc. (NYSE: BFLY) in its $1.5 billion business combination with Longview Acquisition Corp.
• DermTech, Inc. (Nasdaq:DMTK) in its business combination with Constellation Alpha Capital Corp.
• Solarflare Communications, Inc. in its approximately $400 million merger with Xilinx, Inc. (Nasdaq:XLNX)
• Karmadata, Inc. in its sale to Tabula Rasa HealthCare Inc. (Nasdaq:TRHC)
• Quantum-Si Incorporated (Nasdaq:QSI) in its acquisition of Majelac Technologies LLC
• Enterprise Networking Solutions Inc. in its sale to Fulcrum Technology Group

Capital Markets Transactions

• CervoMed Inc. in its $149.4 million PIPE financing
• The selling securityholders in a $198.5 million underwritten secondary offering of Symbotic Inc. (Nasdaq: SYM) common stock
• GRI Bio, Inc. in its $5.5 million public offering
• DermTech, Inc. in its $65 million PIPE financing, $143.7 million underwritten public offering and at-the-market offerings
• Inhibrx, Inc. in its $137 million initial public offering
• Fulgent Genetics, Inc. in underwritten and at-the-market offerings
• Exagen Inc. in its $50 million at-the-market offering

Venture Capital and Emerging Companies

• Classy, Inc. in venture financings
• Xendee Corporation in its $12 million Series A financing
• FAScinate Therapeutics in its Series A financing
• Curvo Labs, Inc. in its $2 million Series A financing
• Decon7 Systems, Inc. in its financing transaction with Johnsonville Holdings, Inc.
• Oberon Fuels, Inc. in multiple financings
• Interleukin Combinatorial Therapies in its Series A-1 financing